Beam Therapeutics Explained

Beam Therapeutics Inc.
Type:Public
Isin:US07373V1052
Industry:Biotechnology
Num Employees:341 (December 31, 2021)[1]

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR and prime editing, whereby single nucleotides in a DNA sequence can be modified without cutting the DNA, theoretically reducing the likelihood of off-target effects compared to previous CRISPR-based methods.[2] [3]

History

Founded in 2017, the company traces its origins to the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Co-founders include David R. Liu and Feng Zhang.[4] Prior to its IPO, the company raised nearly $1 billion in venture capital from investors. In a February 2020 IPO, the company raised $180 million.[5]

In January 2022, Pfizer and Beam Therapeutics announced a collaboration to develop therapies for rare diseases using CRISPR.[6] [7]

See also

Notes and References

  1. Web site: Beam Therapeutics Inc. FORM 10-K . . 14 December 2022.
  2. Web site: Why Beam Therapeutics Climbed 64.5% in June. live. NASDAQ. https://web.archive.org/web/20210807085831/https://www.nasdaq.com/articles/why-beam-therapeutics-climbed-64.5-in-june-2021-07-08 . 2021-08-07 .
  3. Web site: Sterling. John. 2021-07-15. Base Editing Shows Promise as Common Inherited Lung and Liver Disease Therapy. 2021-08-07. GEN - Genetic Engineering and Biotechnology News. en-US.
  4. Book: Isaacson, Walter. Walter Isaacson . The Code Breaker. Simon & Schuster. 2021. 978-1-9821-1585-2. 461–462.
  5. Web site: Dunn. Andrew. Investors are betting billions that cutting-edge cures can upend how we treat heart disease and transform pharma. 2021-08-07. Business Insider. en-US.
  6. Web site: Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases. Pfizer.
  7. Web site: Alpert. Bill. Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases. 2022-02-04. www.barrons.com. en-US.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Beam Therapeutics".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.